Sirolimus goes under the microscope
MacuSight has initiated a phase I study of its proprietary formulation of sirolimus to evaluate its safety and efficacy as a treatment for wet age-related macular degeneration (AMD).
MacuSight has initiated a phase I study of its proprietary formulation of sirolimus to evaluate its safety and efficacy as a treatment for wet age-related macular degeneration (AMD).
The randomized, open-label, dose escalation trial will enrol 30 patients to receive a single injection of sirolimus. There are to be six treatment arms with patients receiving one of three doses of the formulation via a subconjunctival injection or one of three doses via intravitreal injection.
Sirolimus is a broad-acting compound that is able to combat disease through multiple mechanisms of action including anti-angiogenesis, immunosuppression, anti-migration, anti-proliferation, anti-fibrosis and anti-permeability.
MacuSight recently initiated a similar phase I trial of the formulation in patients with diabetic macular oedema.
